Clinical Trials Logo

Purpura, Thrombocytopenic clinical trials

View clinical trials related to Purpura, Thrombocytopenic.

Filter by:

NCT ID: NCT00251277 Withdrawn - Clinical trials for Thrombotic Thrombocytopenic Purpura

Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura

Start date: November 2005
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose is to evaluate safety and feasibility of the use of Rituximab as an adjunct to standard therapy (plasmapheresis + steroids) for patients with thrombotic thrombocytopenic purpura (TTP). This includes evaluating the rate and type of treatment failure.

NCT ID: NCT00161564 Withdrawn - Clinical trials for Idiopathic Thrombocytopenic Purpura (ITP)

A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone

Start date: February 2004
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to compare the efficacy and safety of higher doses of rituximab to a combination of standard doses of Rituxan + CVP (Cyclophosphamide, Vincristine, and Prednisone) in patients with chronic Idiopathic Thrombocytopenic Purpura (ITP who did not respond to or relapsed after standard doses of rituximab.